| Summary: | Background: The optimal conditioning regimen of tandem high-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT) for high-risk neuroblastoma (HR-NBL) has not been established. The efficacy of <sup>131</sup>I-MIBG therapy is under exploration in newly diagnosed HR-NBL patients. Here, we compared the outcomes of tandem HDC/ASCT between the <sup>131</sup>I-MIBG combination and non-MIBG groups. Methods: We retrospectively analyzed the clinical data of 33 HR-NBL patients who underwent tandem HDC/ASCT between 2007 and 2021 at the Seoul National University Children’s Hospital. Results: The median age at diagnosis was 3.6 years. <sup>131</sup>I-MIBG was administered to 13 (39.4%) of the patients. Thirty patients (90.9%) received maintenance therapy after tandem HDC/ASCT, twenty-two were treated with isotretinoin ± interleukin-2, and eight received salvage chemotherapy. The five-year overall survival (OS) and event-free survival (EFS) rates of all patients were 80.4% and 69.4%, respectively. Comparing the <sup>131</sup>I-MIBG combined group and other groups, the five-year OS rates were 82.1% and 79.7% (<i>p</i> = 0.655), and the five-year EFS rates were 69.2% and 69.6% (<i>p</i> = 0.922), respectively. Among the adverse effects of grade 3 or 4, the incidence of liver enzyme elevation was significantly higher in the non-<sup>131</sup>I-MIBG group. Conclusions: Although tandem HDC/ASCT showed promising outcomes, the <sup>131</sup>I-MIBG combination did not improve survival rates.
|
|---|